INTRODUCTION
The annual National Birth Defects Prevention Network (NBDPN) Congenital Malformations Surveillance Report includes state-level data on major birth defects (i.e., conditions present at birth that cause adverse structural changes in one or more parts of the body) and a directory of population-based birth defects surveillance systems in the United States. Beginning in 2012, these annually updated data and directory information are available in an electronic format accompanied by a data brief. This year's report includes data from 41 population-based birth defects surveillance programs and a data brief highlighting the more common trisomy conditions (i.e., disorders characterized by an additional chromosome): trisomy 21 (commonly referred to as Down syndrome), trisomy 18, and trisomy 13. Down syndrome is the most common of these three aneuploidies, occurring in approximately 1 in 691 live births in the United States (Parker et al., 2010) . This is followed by trisomy 18, affecting approximately 1 in 3762 live births and trisomy 13, affecting approximately 1 in 7906 live births (Parker et al., 2010) .
Ascertainment of trisomy cases among the population-based birth defects surveillance systems includes a range of prenatal and postnatal data sources. These can include administrative databases, such as hospital discharge data, vital records, and Medicaid databases; in-patient and out-patient medical records; and specialty facilities, such as cytogenetic laboratories and prenatal diagnostic facilities. Approximately one-third of the birth defects programs use trained staff or abstractors who review medical records for case finding (active case-finding) while approximately two-thirds rely on hospital reporting and/or administrative databases (passive case-finding). Some of the programs with passive case-finding methodology engage in follow-up activities to confirm the reported cases. State-specific data sources and methodologies are included in the state birth defects surveillance program directory, available on-line S122-S172. Table 2 presents the counts and live birth prevalence for Down syndrome by six maternal age categories (Table 2a) and by maternal race/ethnicity (Table 2b ). The list of states is grouped by pregnancy outcomes reported: live births only, live births and stillbirths, or all pregnancy outcomes. The same stratifications are presented for trisomy 18 and 13 in Tables  3 and 4 , respectively. A graphical presentation of the pooled prevalence of state programs by pregnancy outcomes and maternal age group for the trisomies is presented in Figures 1-3 . The states that contributed to the pooled prevalence are listed in Tables 2 to 4.   Table 5 highlights the change in prevalence of Down syndrome, trisomy 18 and trisomy 13 by pregnancy outcome during this data reporting period (2006) (2007) (2008) (2009) (2010) compared with an earlier reporting period (2000) (2001) (2002) (2003) (2004) , as published in the 2007 NBDPN Annual Report (NBDPN, 2007) .
Trisomy Data Presentation

DISCUSSION Data Sources
Variability in the observed prevalence of trisomies across states could be due to true differences; however, other reasons may account for the differences observed, including case ascertainment methodology, ability of a surveillance system to capture all affected cases, and state variations for risk factors such as the distribution of maternal age in these populations. State programs vary in the number and type of data sources used to capture cases. The NBDPN data request stipulated that the birth defect counts provided for the report must be based on multiple data sources (not just vital records); however, the number of additional data sources can differ depending on state legislation, data access, and resources. Cragan and Gilboa (2009) noted that the inclusion of prenatal records from perinatal offices and maternal-fetal medicine departments increased the prevalence of chromosomal abnormalities by over 30%. Similarly, Tao et al. (2013) reported an increase of nearly 8% of all cases of chromosomal abnormalities for the reporting years [2008] [2009] [2010] in the New York surveillance registry by including cytogenetic laboratory reports.
Pregnancy Outcomes
In addition to data sources, another possible variation in the reported prevalence is the inclusion of different pregnancy outcomes in the case definition. Approximately one-third of the birth defects programs ascertain cases among live births only, one-third ascertain cases among live births and still births, and the remaining one-third capture cases for all pregnancy outcomes. Several factors affect a program's decision to identify cases among pregnancy ending in nonlive births, such as program purpose, legal authority, and the availability of data. For example, a program designed to provide follow-up services for affected individuals might only ascertain cases among live births.
However, to understand the full impact of trisomies on the population, it is important to consider all pregnancy outcomes. The pooled prevalence from states with all pregnancy outcomes consistently show a higher prevalence, as presented in Figures 1-3 , than the pooled prevalence from states with live births only or states with live births and stillbirths. Crider et al. (2008) reported a prevalence of trisomy 18 among live births only at 1.16 cases per 10,000 live births; among all pregnancy outcomes combined (live births, stillbirths, and elective terminations), the prevalence increased to 4.01 cases per 10,000 live births. Similarly, the prevalence of trisomy 13 changed from 0.63 per 10,000 live births for live births only to 1.57 per 10,000 live births for all pregnancy outcomes combined. Jackson et al. (2013) also reported a shift in the prevalence of Down syndrome from 11.5 per 10,000 live births for cases among live births only to 16.3 per 10,000 live births for cases among all pregnancy outcomes.
Prenatal Testing
Prenatal testing allows for a more accurate ascertainment of cases by surveillance systems, especially if they are diagnosed and captured in medical records. Prenatal diagnostic testing and elective termination have been shown to affect the live birth prevalence of Down syndrome (Mikkelsen, 1992; Cornel et al., 1993; Krivchenia et al., 1993; Bishop et al., 1997; Forrester and Merz, 1999) and of trisomies 18 and 13 (Crider et al., 2008) . Noninvasive screening methods such as maternal protein serum assays and ultrasound have become more accurate and are being used with increasing frequency (Baker et al., 2004; Benn et al., 2004; Ekelund et al., 2008; Nakata et al., 2010) . Additionally, a recent method of noninvasive prenatal testing that uses cell free fetal DNA collected from maternal blood has recently been used to screen for Down syndrome, trisomy 18, and trisomy 13 (Langlois et al., 2013) . This method shows much promise as a screening tool and will likely result in a change in prevalence if early terminations are missed by states that capture all pregnancy outcomes. The data presented in this data report are not affected by cell free fetal DNA analysis because this screening tool was not commonly used/ employed until recently; however, as all noninvasive prenatal screening and testing methods increase in use, the effect on prevalence estimates derived from population-based birth defects surveillance systems will need to be monitored. The frequency with which prenatal detection results in elective pregnancy termination varies among states; opinions about and the use of elective pregnancy termination have been shown to differ by age, race/ethnicity, religion, socioeconomic status, marital status, and type of health insurance (Harris and Mills, 1985; Jones et al., 2010; Pazol et al., 2011) .
Maternal Age
Maternal age is the most consistent risk factor associated with increased prevalence (Hecht and Hook, 1996; Mikkelsen, 1985) . As expected, the prevalence consistently increases by maternal age as shown in Figures 1-3 . However, surveillance systems that do not collect cases from all pregnancy outcomes are more likely to under-ascertain cases in the older maternal age groups than in the younger groups; this is more pronounced for trisomy 18 and 13 than for Down syndrome. The data suggest that pregnancy loss (e.g., stillbirths, terminations) is more common among advanced maternal age groups. Previous studies have shown an increased risk of stillbirths as well as increased usage of prenatal testing in women 35 years and older (Reddy et al., 2006; Crider et al., 2008; Jackson et al., 2011) .
The maternal age distribution in the United States has shifted toward older ages over the past few decades (Martin et al., 2012) ; however, during the birth period included in this report (2006) (2007) (2008) (2009) (2010) , this trend has remained relatively stable. Although advanced maternal age is a known risk factor for trisomy, advanced paternal age has not been observed to be an independent risk factor after adjusting for maternal age (Janerich and Bracken, 1986; De Souza and Morris, 2010) .
Maternal Race/Ethnicity
There appears to be modest variation in the prevalence of trisomy 13 and 18 by race/ ethnicity, but previous reports have not been consistent. Crider et al. (2008) found the highest prevalence for each among non-Hispanic whites, but others found a lower or no difference in prevalence among non-Hispanic whites compared with Hispanics and nonHispanic blacks (Canfield et al., 2006; Kucik et al., 2012) . Variation in prevalence of Down syndrome by race/ethnicity has been more consistently reported. The prevalence among Hispanics is significantly higher than among non-Hispanic whites, particularly among births to mothers 35 years or older (CDC, 1994; Canfield et al., 2006; Agopian et al., 2012; Kucik et al., 2012) , while non-Hispanic black women have the lowest observed prevalence. These differences may be related to differential use of prenatal diagnostic services (Kupper-mann et al., 1996 (Kupper-mann et al., , 2006 . Jackson et al. (2013) suggest that biological causes, such as maternal age, as well as social factors, such as attitudes regarding elective termination and access to care, might contribute to the race/ethnicity differences observed in the prevalence of Down syndrome.
Trends in Prevalence and Survival
Information on trends in prevalence of trisomy 18 and 13 is sparse (Crider et al., 2008) , but the increasing prevalence of Down syndrome has been documented previously (Shin et al., 2009; Cocchi et al., 2010) . This report provides evidence that this trend continues for Down syndrome, trisomy 18, and trisomy 13. Compared with birth prevalence estimates reported in the 2007 Annual report of the NBDPN, an increase in the pooled prevalence was noted for all three trisomy groups as reported by state programs that included all pregnancy outcomes and by those that reported live births and still births (Table 5) (NBDPN, 2007) . The pooled prevalence among states that reported only live births increased for Down syndrome and trisomy 18 but declined slightly for trisomy 13. From 1979 to 2003 , Shin et al. (2009 reported an increase in the live birth prevalence for Down syndrome from 9.0 to 11.8 per 10,000 live births, so the live birth prevalence in this report supports a continuing increase.
Although trisomy 13 and 18 are nearly always fatal (Rasmussen et al., 2003; Vendola et al., 2010) , the improved survival of those born live with Down syndrome has been previously documented (Kucik et al., 2013; Zhu et al., 2013) with the most recent 1-year survival probability (birth period 1997-2003) estimated as high as 94% (Kucik et al., 2013) . The greatest survival improvement has been observed among those individuals with Down syndrome born of low birth weight or with a co-occurring congenital heart defect (Kucik et al., 2013; Zhu et al., 2013) , which is the leading cause of death among infants and children with Down syndrome (Shin et al. 2007; Zhu et al., 2013) .
CONCLUSIONS
This data report provides state-specific birth defects data from 41 population-based birth defects surveillance programs in the United States and continues to be an important data source to understand the impact of these conditions. The focus on trisomy conditions highlights continuing trends and underscores the importance of accounting for differences in ascertainment and reporting practices to fully understand the variation in prevalence by state. With the increasing prevalence of trisomies and improved survival of affected individuals, this report serves as an important notice to clinicians, health officials, and health care planners of the growing public health importance of trisomies; additionally, it suggests the need for more research on the role of prenatal detection in improving postnatal health and health service planning that addresses the lifetime needs of a growing population.
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